WEED - The Final Frontier

[Crypto__1]

Micro Cap Update on Viaderma Inc ($VDRM)

Micro Cap Update on Viaderma Inc (OTCMKTS: $VDRM)
By Gene Daniel -  May 7, 2017

Viaderma Inc (OTCMKTS:VDRM) has been one of the more active micro caps in recent months. Advertising around MSD (Male Sexual Dysfunction) drugs like Cialis and Viagra dominate sports programming, so the taboo nature of the discussion has subsided over the years. But it is still surprising when you see a stock like Viaderma Inc (OTCMKTS:VDRM) take off, but some digging showed that this falls into the cannabis sector and the share price move is related to the theme of replacing pharma with CBD’s. But this should not surprise those who follow the Erectile Dysfunction (ED) market which is dominated by Cialis and Viagra. But this stock is based on the sales of the topical market for ED, and the growth of medical cannabis.

A look at the price action is a different story, it has been a story of peaks and valleys as investors get their hands around how these shares fit in the cannabis sector.  But look at the yearly chart, and you will see this reflected in the price and volume, and the volatility that comes with new hot sectors. Those who are in the stock know it is up 500% for the year and were as high as +2000% at it’s peak. Volatility in new markets will stay with cannabis for many years so get used to it – it is the toll you pay – to invest and achieve these outsized returns.

Viaderma Inc (OTCMKTS:VDRM) is a specialty pharmaceutical company devoted to bringing new products to market, recently announced that the Company has filed with the (FDA) Food and Drug Administration for a new over the counter or OTC version of its “Premature Ejaculation Drug”. The new “OTC Drug” should have FDA registration approval in approximately 8 weeks and the Company’s name of the new drug will portray prolonged endurance. The Company says it’s recent testing of the drug has proved to be successful in retarding the onset of ejaculation during sexual intercourse.

The market for male sexual dysfunction is dominated by #Viagra and #Cialis both are taken orally for Erectile Dysfunction (ED). The Company’s alternative is a topical solution that does not have to be ingested and processed through the digestive system. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues starting in 2017.

Subscribe below and we’ll keep you on top of what’s happening before $VDRM stock makes its next move.



$VDRM 10-Day Chart Below: Premature ejaculation (PE) is the most common male sexual disorder, and it may have a profound negative impact on a man and his partner’s lives. Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company.

In the US, topical sprays that treat PE are available OTC. In reported testing these types of products work on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment segment of the sexual dysfunction market has been estimated to be $1.3 Billion dollars for 2017. Also, reported, the market for these types of products could become larger than the tablet or oral (ED) market.

ViaDerma, Inc. (OTCMKTS: $VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD’s and THC with the delivery system was filed in 2014. The use of CBD’s is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.

This is an innovative story with a Cannabis twist that replaces synthetics with a natural drug, which has been a positive theme in all small company trades occurring in 2017. It is worth watching how this plays out in this niche market. Shares have been much higher than they are now, but recent bounces may show the company is getting some traction.

We like these natural replacement drugs where a synthetic drug is being replaced by a CBD, and investors like investing in these stocks as they emerge. Investors are beginning to understand, through recent price action, that pharmaceutical companies as we know them are changing forever and for always.


http://oracledispatch.com/2017/05/07/micro-cap-update-viaderma-inc-otcmktsvdrm/ via @Oracle Dispatch